Nightstar Therapeutics

About:

Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies.

Website: https://www.nightstartx.com

Top Investors: New Enterprise Associates, Wellington Management, Redmile Group, Syncona Partners LLP

Description:

NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.

Total Funding Amount:

$99.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2013-01-01

Contact Email:

enquiries(AT)nightstarx.com

Founders:

Matthew J. During

Number of Employees:

11-50

Last Funding Date:

2017-06-30

IPO Status:

Delisted

Industries: